These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26988222)

  • 1. Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors.
    Lucchesi M; Guidi M; Fonte C; Farina S; Fiorini P; Favre C; de Martino M; Sardi I
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):857-64. PubMed ID: 26988222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia.
    Lönnerholm G; Valsecchi MG; De Lorenzo P; Schrappe M; Hovi L; Campbell M; Mann G; Janka-Schaub G; Li CK; Stary J; Hann I; Pieters R;
    Pediatr Blood Cancer; 2009 May; 52(5):596-601. PubMed ID: 19132729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
    Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigation on individualized adjustment of target range of high-dose methotrexate].
    Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
    Donelli MG; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi MR
    Med Pediatr Oncol; 1995 Mar; 24(3):154-9. PubMed ID: 7838036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
    Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
    Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
    Chan BS; Dawson AH; Buckley NA
    Clin Toxicol (Phila); 2017 Feb; 55(2):88-96. PubMed ID: 28084171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia.
    Thompson PA; Murry DJ; Rosner GL; Lunagomez S; Blaney SM; Berg SL; Camitta BM; Dreyer ZE; Bomgaars LR
    Cancer Chemother Pharmacol; 2007 May; 59(6):847-53. PubMed ID: 17136402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours.
    Panetta JC; Roberts JK; Huang J; Lin T; Daryani VM; Harstead KE; Patel YT; Onar-Thomas A; Campagne O; Ward DA; Broniscer A; Robinson G; Gajjar A; Stewart CF
    Br J Clin Pharmacol; 2020 Feb; 86(2):362-371. PubMed ID: 31657864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
    Chládková J; Hak J; Martínková J; Chládek J
    Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy.
    Dupuis C; Mercier C; Yang C; Monjanel-Mouterde S; Ciccolini J; Fanciullino R; Pourroy B; Deville JL; Duffaud F; Bagarry-Liegey D; Durand A; Iliadis A; Favre R
    Anticancer Drugs; 2008 Mar; 19(3):267-73. PubMed ID: 18510172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
    Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
    Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
    Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
    Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.